CervoMed price target lowered to $11 from $19 at Roth Capital

Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on CervoMed (CRVO) to $11 from $19 and keeps a Buy rating on the shares. The company’s Q4/FY25 financial results and corporate update were largely aligned with the firm’s expectations, the analyst tells investors in a research note. While the company’s 2H26 calendar is heavily loaded with multiple catalysts, the firm earnestly looks forward to Phase 3 Dementia with Lewy Bodies study initiation, given “solid” Phase 2 OLE study results and the first-mover advantage. The firm added that it cut its price target based on model updates reflecting the need to raise capital under less attractive terms.